Ionis Pharmaceuticals Announces Completion of Public Offering

Details

completed a public offering of 11,500,000 shares of its common stock at a price of $43.50 per share, raising approximately $500.3 million before underwriting discounts and commissions. The offering was underwritten by Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC. An additional 30-day option to purchase up to 1,725,000 shares was granted to the underwriters. The offering closed on September 11, 2024, pursuant to the company's effective registration statement on Form S-3.

Items reported

Exhibits (2)

About Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.